You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Details for Patent: 4,355,032


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,355,032
Title:9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent
Abstract:The compound 9-(1,3-dihydroxy-2-propoxymethyl)guanine and the pharmaceutically acceptable salts thereof are useful as antiviral agents.
Inventor(s):Julien P. Verheyden, John C. Martin
Assignee:Hoffmann La Roche Inc, Syntex USA LLC, Roche Holdings Inc
Application Number:US06/267,210
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent landscape, scope, and claims:

Analysis of US Patent 4,355,032: Scope, Claims, and Patent Landscape

What is the Scope and Content of US Patent 4,355,032?

US Patent 4,355,032 was granted on October 19, 1982, to Hercules Inc. It is titled "Process for preparing organosilane compositions." The patent covers a process for synthesizing specific organosilane compounds, notably those with applications in coatings, adhesives, and sealants. The patent's primary focus involves the preparation of organosilanes through the hydrolysis and condensation of chlorosilanes.

The patent claims a process that involves reacting an alkyl or aryl chlorosilane with water, in the presence of a catalytic amount of acid or base, under controlled conditions to produce silanols and subsequently condensate to form organosilane compositions. The process emphasizes controlling parameters such as temperature, reaction time, and catalyst concentration to yield specific silanol structures with targeted functionalities.

What Are the Main Claims of US Patent 4,355,032?

Claim 1 (Independent Claim)

The broadest claim defines the process:

"A process for preparing organosilane compositions, comprising reacting an organochlorosilane with water in the presence of a catalytic amount of acid or base under controlled conditions to yield a composition containing organosilanols and their condensates."

This claim covers the fundamental method for synthesizing organosilanes via hydrolysis-condensation.

Subsequent Claims (Dependent Claims)

Dependent claims specify parameters such as:

  • Types of chlorosilanes (e.g., methylchlorosilane, phenylchlorosilane).
  • Reaction temperatures (generally between room temperature and 100°C).
  • Catalyst types (hydrochloric acid, sodium hydroxide).
  • Solvent conditions and purification steps.

Claim Scope Summary

The scope is broad, encompassing various chlorosilanes and reaction conditions, which has implications for potential infringement and licensing strategies. The patent does not specify particular organosilane structures but covers the general hydrolysis-condensation process.

What Does the Patent Landscape Look Like for Organosilane Synthesis?

Key Patents in the Field

  • US Patent 4,344,982 (assigned to Dow Corning) covers the synthesis and application of specific methylsilicone resins, filed shortly before US 4,355,032.
  • EP Patent 0,097,252 (European Patent) covers similar hydrolysis processes with specific modifications to improve yield and control.
  • US Patent 4,517,216 discusses the use of organosilane intermediates for forming silica-based composites, indicating downstream applications.

Patent Clusters and Therapeutic/Industrial Segments

While US 4,355,032 primarily relates to material synthesis, similar patents appear in the subsequent decades focusing on:

  • Coatings and adhesives in construction and electronics.
  • Sealants and anti-corrosion formulations.
  • Cross-linked silicone elastomers for medical and industrial use.

Patent families often include claims around specific use-cases and formulations, indicating a development trend from pure chemical processes toward application-specific innovations.

Recent Patent Activity

Patent filings related to organosilane processes have declined in recent years, with most activity focusing on:

  • Improved catalytic processes.
  • Non-toxic and environmentally benign solvent systems.
  • Novel functional organosilanes for bioapplications.

Leading patent filers include Dow Corning, Momentive Performance Materials, and Wacker Chemie.

Patent Expirations and Freedom-to-Operate

US patents filed before the mid-1980s, including 4,355,032, have generally expired due to age, opening opportunities for generic synthesis routes. However, subsequent patents extending process modifications or specific applications may still restrict certain practices.

What Are the Implications for Industry and R&D?

  • The broad scope of US 4,355,032 enables a wide range of synthesis methods, but innovation now focuses on improving efficiency, environmental safety, and application-specific functionalities.
  • Patent landscape suggests active development in downstream applications rather than fundamental process patents anymore, which are now largely in the public domain.
  • Freedom-to-operate analyses should scrutinize current patent families related to process modifications or specific uses.

Key Takeaways

  • US Patent 4,355,032 claims a broad process for preparing organosilanes via hydrolysis of chlorosilanes with catalysts.
  • The patent's claims encompass various chlorosilanes, reaction conditions, and catalysts, offering wide coverage for synthesis methods.
  • The patent landscape features related patents mainly focused on specific applications, functional modifications, and improvements to the process.
  • Most patents predating 1987 have expired, but newer patents in related fields could still restrict certain practices.
  • Recent industry activity emphasizes environmental considerations, process optimization, and niche applications for organosilane compounds.

FAQs

Q1: Can the process claimed in US 4,355,032 be freely used today?
A1: Typically, yes, since the patent expired in the early 2000s after 20 years from issuance, unless specific improvements are covered by newer patents.

Q2: How does this patent influence modern organosilane synthesis?
A2: It provides foundational process knowledge; contemporary innovations build on or modify these procedures, often positioning around environmental and efficiency enhancements.

Q3: Are there alternative synthesis routes not covered by US 4,355,032?
A3: Yes, modern methods include sol-gel processes, non-chlorosilane precursors, and catalytic systems not described in the patent.

Q4: Which industries primarily utilize organosilanes covered by this patent?
A4: Construction (sealants, coatings), electronics (adhesives), and medical devices (elastomers).

Q5: What recent legal developments could impact patents related to this process?
A5: Although the original patent has expired, ongoing patent filings have focused on novel functionalization and environmentally friendly processes, which could restrict certain applications.

References

  1. US Patent 4,355,032. (1982). Process for preparing organosilane compositions. U.S. Patent and Trademark Office.
  2. US Patent 4,344,982. (1982). Organosilicone resins. U.S. Patent and Trademark Office.
  3. European Patent 0,097,252. (1982). Hydrolysis process for organosilanes. European Patent Office.
  4. US Patent 4,517,216. (1985). Organosilane intermediates for silica composites. U.S. Patent and Trademark Office.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 4,355,032

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.